RYR1 and congenital myopathy with cores: There is little evidence which links metabolic processes to congenital myopathies, although certain therapies such as N-acetylcysteine have been studied to reduce the deleterious effects of oxidative stress on muscle damage in human recessive RYR1-related myopathies [27].